Through the agreement, BMS will supply its best-selling cancer drug Opdivo for Bavarian Nordic to use in a clinical trial.
The study, expected to include around 160 patients, will examine the efficacy of combining its drug CV301 with Opdivo in patients with previously untreated non-small cell lung cancer.
Bavarian Nordic will maintain all commercial rights for CV301.
The study is expected to start later this year.
More articles on the drug market:
Secretive board at Express Scripts determines drug exclusions
Aurobindo Pharma to open vaccine manufacturing facility
Lethal drug poses new threat to the opioid epidemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
